Analysts Set Expectations for VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 13th. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will post earnings per share of ($1.55) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

Several other analysts have also recently commented on VNDA. StockNews.com began coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th.

Vanda Pharmaceuticals Price Performance

VNDA opened at $3.93 on Thursday. The business has a 50 day simple moving average of $4.44 and a 200-day simple moving average of $4.63. The stock has a market capitalization of $231.61 million, a P/E ratio of -12.28 and a beta of 0.69. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The business had revenue of $50.04 million during the quarter, compared to analysts’ expectations of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth $48,000. Linden Thomas Advisory Services LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter valued at about $49,000. Nations Financial Group Inc. IA ADV purchased a new stake in Vanda Pharmaceuticals during the first quarter valued at about $67,000. XTX Topco Ltd acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $69,000. Finally, Virtu Financial LLC acquired a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $72,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the acquisition, the chief executive officer now owns 2,361,730 shares in the company, valued at $11,241,834.80. This trade represents a 0.43% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders acquired 32,000 shares of company stock valued at $151,180 in the last three months. 10.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.